Article
Chemistry, Multidisciplinary
Siming Yuan, Yang Zhu, Yi Dai, Yu Wang, Duo Jin, Manman Liu, Liqin Tang, Fabio Arnesano, Giovanni Natile, Yangzhong Liu
Summary: Pt-IV prodrugs can overcome resistance and side effects of conventional Pt-II anticancer therapies by efficiently promoting the two electrons reduction of Pt-IV to Pt-II. The activation of Pt-FBA is highly dependent upon the type of cancer cells, and FBA can shuttle out of the cell after Pt-FBA is reduced intracellularly. The F-19 NMR approach has the advantage of avoiding the interference of all background signals when investigating the activation of Pt-IV prodrugs.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2022)
Article
Biochemistry & Molecular Biology
Meng Wang, Zhikun Liu, Xiaochao Huang, Yuanhang Chen, Yanming Wang, Jing Kong, Yong Yang, Chunhao Yu, Jin Li, Xu Wang, Hengshan Wang
Summary: Novel dual target platinum(IV) complexes showed effective antitumor activities with lower toxicity and resistance factors than standard platinum-based chemotherapeutics, by modulating proapoptosis and prosurvival protein expression levels in cancer cells through mitochondrial dysfunction-induced mechanisms. Compound 11 has the potential to be a lead compound for future cancer therapy due to its potency and selectivity.
BIOORGANIC CHEMISTRY
(2021)
Review
Biochemistry & Molecular Biology
Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
Summary: This review summarizes the research on the development of Pt(IV) prodrugs with NSAIDs as axial ligands, their cytotoxic action and anti-inflammatory activity mechanism studies, structure-activity ratio, and therapeutic efficacy. The chemo-anti-inflammatory strategy aims to efficiently deliver cytotoxic metabolites and NSAIDs intracellularly in tumor cells to reduce side effects and increase therapeutic efficacy. Studies have shown high therapeutic efficacy both in vitro and in vivo.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Daniil Spector, Kirill Pavlov, Elena Beloglazkina, Olga Krasnovskaya
Summary: Pt(IV) prodrugs with a light-controlled mode of activation show high antiproliferative activity when irradiated, but are non-toxic in the absence of light. This review discusses recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs, focusing on the photocatalytic strategy based on flavin derivatives and the conjugation of photoactive molecules with Pt(II) drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Aleen Khoury, Jennette A. Sakoff, Jayne Gilbert, Kieran F. Scott, Shawan Karan, Christopher P. Gordon, Janice R. Aldrich-Wright
Summary: Platinum(IV) prodrugs showed outstanding activity against various cancer cell lines, with nanomolar activities observed. Cellular accumulation of the complexes was correlated with increased cytotoxicity. COX inhibition or lipophilicity did not solely determine the cytotoxicity of these prodrugs.
Article
Chemistry, Multidisciplinary
Alexander Kastner, Hemma Schueffl, Patrick A. Yassemipour, Bernhard K. Keppler, Petra Heffeter, Christian R. Kowol
Summary: Platinum(IV) prodrugs are promising alternatives to platinum(II) anticancer therapeutics. This study investigated the reactivity and synthetic usability of a platinum(IV) complex with hydrolyzable equatorial ligands, and successfully synthesized stable platinum(IV) complexes suitable for long-circulating tumor-targeting strategies. Additionally, platinum(IV) complexes with equatorial maleimides were synthesized, showing prolonged plasma half-life and improved anticancer activity compared to oxaliplatin.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Review
Chemistry, Inorganic & Nuclear
Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu
Summary: Platinum-based anticancer drugs have been widely used in clinical practice for over 40 years, with a focus on developing platinum(IV) prodrugs based on traditional platinum(II) anticancer drugs. Recent progress in the field includes synthesizing platinum(IV) prodrugs with new oxidizing reagents, understanding the hydrolysis and stability of platinum(IV) complexes, and exploring reduction processes to achieve controllable intracellular reduction of platinum(IV) prodrugs. This review aims to enhance researchers' understanding of platinum(IV) anticancer prodrugs and inspire new strategies, ideas, and applications in metal-based drugs.
COORDINATION CHEMISTRY REVIEWS
(2021)
Article
Chemistry, Inorganic & Nuclear
Paride Papadia, Alessandra Barbanente, Nicoletta Ditaranto, James D. Hoeschele, Giovanni Natile, Cristina Marzano, Valentina Gandin, Nicola Margiotta
Summary: Six enantiomerically pure, oxaliplatin-like platinum compounds with unsaturated cyclic diamine as a substitute for oxaliplatin were investigated for their promising antiproliferative activities, showing potential in overcoming resistance to platinum-based drugs. The R,R enantiomer was found to be most effective in Pt(ii) complexes while the S,S enantiomer showed greater efficacy in Pt(iv) derivatives, suggesting potential for further preclinical investigation.
DALTON TRANSACTIONS
(2021)
Review
Chemistry, Inorganic & Nuclear
Chunyan Jia, Glen B. Deacon, Yingjie Zhang, Chuanzhu Gao
Summary: This article summarizes the main problems of platinum-based anticancer drugs, introduces Pt-IV drugs and their characteristics, and focuses on the combination therapy with nanocarriers, looking forward to the application prospects of Pt-IV drugs and nanotechnology in the field of cancer chemotherapy.
COORDINATION CHEMISTRY REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Man Kshetri, Wjdan Jogadi, Suha Alqarni, Payel Datta, May Cheline, Arpit Sharma, Tyler Betters, Deonya Broyles, Yao-Rong Zheng
Summary: We conducted the first comprehensive investigation on the impact of head group modifications on the anticancer activities of fatty-acid-like Pt(IV) prodrugs (FALPs). We created a small library of FALPs with diverse head group modifications and found that hydrophilic modifications enhanced the potency of these metallodrugs, while hydrophobic modifications decreased their cytotoxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Anife Ahmedova, Rositsa Mihaylova, Silviya Stoykova, Veronika Mihaylova, Nikola Burdzhiev, Viktoria Elincheva, Georgi Momekov, Denitsa Momekova
Summary: Pt(IV) complexes formed by linking pyrene butyric acid with cisplatin exhibit high anticancer potency against leukemia cells and multidrug-resistant derivatives, while showing low toxicity to healthy cells. The larger bis-pyrene complex is found to potentially be trapped in the cytoskeleton, limiting its cytotoxicity to adherent cells.
Article
Chemistry, Multidisciplinary
Xuxian Su, Bin Liu, Wen-Jin Wang, Kun Peng, Bing-Bing Liang, Yue Zheng, Qian Cao, Zong-Wan Mao
Summary: This study developed a novel cyclometalated Pt-IV-terthiophene complex, Pt3, that disrupts zinc homeostasis and induces cell apoptosis, thereby activating anti-tumor immunity and eliminating tumors.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Article
Biochemistry & Molecular Biology
Marie-Christin Barth, Norman Haefner, Ingo B. B. Runnebaum, Wolfgang Weigand
Summary: The research explores the anticancer potential of platinum(IV) complexes and investigates the effects of non-steroidal anti-inflammatory drug (NSAID) ligands on their cytotoxicity. The synthesis and characterization of nine platinum(IV) complexes are presented, and their cytotoxic activity is evaluated against ovarian carcinoma cell lines. The most promising complex, Compound 7, induces cell cycle arrest and apoptosis or necrosis in a cell line-dependent manner, acting through a stress response pathway involving p21, CHOP, and ATF3 genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Qiyuan Zhou, Shu Chen, Zoufeng Xu, Gongyuan Liu, Shuyuan Zhang, Zhigang Wang, Man-Kit Tse, Shek-Man Yiu, Guangyu Zhu
Summary: This study reports the synthesis of Pt-IV complexes bearing axial pyridines through ligand exchange reactions. It was discovered that these axial pyridines can be quickly released after reduction, indicating their potential as axial leaving groups. Two multitargeted Pt-IV prodrugs containing bioactive pyridinyl ligands, a PARP inhibitor and an EGFR tyrosine kinase inhibitor, were successfully obtained using this method. These conjugates show great potential for overcoming drug resistance, with the latter inhibiting the growth of Pt-resistant tumor in vivo. This research expands the synthetic methods for Pt-IV prodrugs and increases the range of bioactive axial ligands that can be conjugated to a Pt-IV center.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Article
Pharmacology & Pharmacy
Aleen Khoury, Jennette A. Sakoff, Jayne Gilbert, Shawan Karan, Christopher P. Gordon, Janice R. Aldrich-Wright
Summary: Four platinum(IV) prodrugs incorporating a biotin moiety showed exceptional cytotoxicity against cancer cell lines. One of the prodrugs exhibited the lowest cytotoxicity in prostate cancer cells, while another prodrug showed higher activity in colon cancer cells. Some prodrugs also demonstrated selectivity towards breast cancer cells compared to healthy cells, which was not observed with their platinum(II) precursors.
Article
Chemistry, Multidisciplinary
Daniel Charles Ashley, Mu-Hyun Baik
CHEMISTRY-A EUROPEAN JOURNAL
(2015)
Article
Chemistry, Multidisciplinary
Douglas W. Crandell, Soumya Ghosh, Curtis P. Berlinguette, Mu-Hyun Baik
Article
Chemistry, Inorganic & Nuclear
Rick Thompson, Ba L. Tran, Soumya Ghosh, Chun-Hsing Chen, Maren Pink, Xinfeng Gao, Patrick J. Carroll, Mu-Hyun Baik, Daniel J. Mindiola
INORGANIC CHEMISTRY
(2015)
Article
Chemistry, Inorganic & Nuclear
Tufan K. Mukhopadhyay, Nicholas L. MacLean, Lu Gan, Daniel C. Ashley, Thomas L. Groy, Mu-Hyun Baik, Anne K. Jones, Ryan J. Trovitch
INORGANIC CHEMISTRY
(2015)
Article
Chemistry, Inorganic & Nuclear
Douglas W. Crandell, Haiyang Zhu, Xiaofan Yang, John Hochmuth, Mu-Hyun Baik
INORGANICA CHIMICA ACTA
(2015)
Article
Chemistry, Multidisciplinary
Balazs Pinter, Kyle T. Smith, Masahiro Kamitani, Eva M. Zolnhofer, Ba L. Tran, Skye Fortier, Maren Pink, Gang Wu, Brian C. Manor, Karsten Meyer, Mu-Hyun Baik, Daniel J. Mindiola
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2015)
Review
Chemistry, Multidisciplinary
Yoonsu Park, Seihwan Ahn, Dahye Kang, Mu-Hyun Baik
ACCOUNTS OF CHEMICAL RESEARCH
(2016)
Article
Chemistry, Organic
Manibarsha Goswami, Daniel C. Ashley, Mu-Hyun Baik, Nicola L. B. Pohl
JOURNAL OF ORGANIC CHEMISTRY
(2016)
Article
Chemistry, Multidisciplinary
Amanda L. Le Sueur, Richard N. Schaugaard, Mu-Hyun Baik, Megan C. Thielges
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2016)
Article
Chemistry, Multidisciplinary
Yoonsu Park, Joon Heo, Mu-Hyun Baik, Sukbok Chang
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2016)
Article
Biochemical Research Methods
Nick DeGraan-Weber, Daniel C. Ashley, Karlijn Keijzer, Mu-Hyun Baik, James P. Reilly
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
(2016)
Article
Chemistry, Inorganic & Nuclear
Meghan C. McCormick, Franklin A. Schultz, Mu-Hyun Baik
Article
Multidisciplinary Sciences
Kyle T. Smith, Simon Berritt, Mariano Gonzalez-Moreiras, Seihwan Ahn, Milton R. Smith, Mu-Hyun Baik, Daniel J. Mindiola
Article
Chemistry, Physical
Daniel Charles Ashley, Mu-Hyun Baik
Article
Biochemistry & Molecular Biology
Hosung Ki, Sungjun Park, Seunghwan Eom, Jain Gu, Siim Kim, Changwon Kim, Chi Woo Ahn, Minseo Choi, Sena Ahn, Doo-Sik Ahn, Jungkweon Choi, Mu-Hyun Baik, Hyotcherl Ihee
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)